Home Fingerprick Blood-Based HIV Self-Test For Quantitative Monitoring Of Viral Rebound

首页指尖采血 HIV 自检，定量监测病毒反弹

基本信息

批准号：
10066088
负责人：
Weihua Guan
金额：
$ 26.36万
依托单位：
PENNSYLVANIA STATE UNIVERSITY, THE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10066088
关键词：
AIDS/HIV problem Acquired Immunodeficiency Syndrome Adherence Age Ambulatory Care Facilities Antibody Response Attitude Awareness Benchmarking Benefits and Risks Biological Assay Blood Blood Glucose Blood specimen Comprehensive Health Care Data Detection Devices Diagnostic tests Drug resistance Early Diagnosis Failure Fingers Guidelines HIV HIV Infections HIV Seronegativity HIV-1 Health Home environment Hybrids Individual Infection Laboratories Lateral Learning Mechanics Mediating Medical center Methods Microfluidic Microchips Microfluidics Monitor Morbidity - disease rate Nucleic Acid Amplification Tests Optics Outcome Participant Patients Perception Performance Phase Plasma Play Population Preparation Privatization Process Public Health RNA Recovery Reporting Research Reverse Transcription Sampling Sensitivity and Specificity Side Specimen Surveys Testing Training Treatment Failure Treatment outcome United States Validation Viral Load result Viral load measurement Virus Whole Blood antiretroviral therapy base cost effective empowered experience high risk population improved innovation mortality operation performance tests prevent programs prototype public health relevance recruit research clinical testing satisfaction screening sex software development time use transmission process treatment adherence usability viral RNA viral rebound

项目摘要

Project Summary/Abstract The advancement of antiretroviral treatment (ART) has significantly reduced the HIV mortality and morbidity by reducing the viral load (VL) to undetectable levels. Recently revised WHO guidelines strongly recommend routine VL testing to monitor ART adherence and minimize failure. To this end, HIV self-testing, a process in which individual who wants to know HIV status collects a specimen, performs a test and interprets the result in private, has become an empowering approach. While nucleic acid testing (NAT) is readily available in centralized laboratories for viral load quantification, its availability in self-testing has not been demonstrated due to sample processing and assay complexity. This project aims to develop a quantitative test on an ultra-compact USB device to detect viral rebound that is simple enough for laypersons to test themselves in the United States. The R61 phase of the project will develop the whole blood-based test that can quantitatively assess the presence of HIV-1 RNA at concentrations as low as 1000 copies/ml, threshold recommended by WHO for determining treatment failure. In aim 1, we will develop a disposable microfluidic chip for streamlined and automated plasma separation and viral RNA extraction from whole blood. In aim 2, we will optimize the HIV-1 RT-LAMP assay and explore the minimum copy number sensitivity. In aim 3, we will integrate the quantitative USB analyzer hardware and develop software for easy and robust operation. In aim 4, we will validate the prototyped test in the BSL-2 lab using HIV-1 plasma samples spiked into whole blood. The R33 phase of the project will assess the test performance, usability and stakeholder needs within the HIV Comprehensive Care Program at Penn State Hershey Medical Center. In aim 5, the performance of the proposed test on HIV-infected patients will be benchmarked with standard laboratory methods. In aim 6, we will evaluate the user’s experience, attitude and perception of HIV VL self-testing. Through innovations in microfluidic chips and the USB analyzer, we anticipate the test would be able to quantify HIV-1 VL as low as 1000 copies/ml directly from 100 µl of finger prick blood. The potential impact of this project is very high. If this proof-of-concept project is successful, it has the potential to significantly enhance the treatment outcomes for individuals of HIV under therapy. The potential transformative capacity warrants the challenges associated with this project.

项目概要/摘要抗逆转录病毒治疗（ART）的进步显着降低了艾滋病毒死亡率和发病率将病毒载量 (VL) 降低至不可检测的水平最近修订的世界卫生组织指南强烈建议采取常规措施。 VL 测试可监测 ART 依从性并最大限度地减少失败。为此，HIV 自我测试是一个过程。想要了解艾滋病毒状况的个人可以私下采集样本、进行测试并解释结果，核酸检测 (NAT) 已成为一种赋权方法。实验室进行病毒载量定量，但由于样本原因，其自检可用性尚未得到证实该项目旨在开发超紧凑 USB 的定量测试。检测病毒反弹的设备对于非专业人士来说足够简单，可以在美国进行自我测试国家。该项目的R61阶段将开发基于全血的测试，可以定量评估是否存在 HIV-1 RNA 浓度低至 1000 拷贝/毫升，这是世界卫生组织推荐的测定阈值在目标 1 中，我们将开发一种用于简化和自动化血浆的一次性微流控芯片。在目标 2 中，我们将优化 HIV-1 RT-LAMP 检测和从全血中分离和提取病毒 RNA。在目标 3 中，我们将集成定量 USB 分析仪硬件。并开发软件以实现简单而稳健的操作在目标 4 中，我们将验证 BSL-2 中的原型测试。实验室使用掺入全血的 HIV-1 血浆样本。该项目的 R33 阶段将评估 HIV 领域的测试性能、可用性和利益相关者需求宾夕法尼亚州立大学好时医疗中心的综合护理计划在目标 5 中，拟议的绩效。在目标 6 中，我们将使用标准实验室方法对 HIV 感染患者进行测试进行评估。用户对 HIV VL 自检的经历、态度和看法。通过微流控芯片和 USB 分析仪的创新，我们预计该测试将能够量化直接从 100 µl 指尖采血中检测到的 HIV-1 VL 低至 1000 拷贝/毫升该项目的潜在影响。如果这个概念验证项目成功，它有可能显着提高接受治疗的艾滋病毒患者的治疗结果具有潜在的变革能力。与该项目相关的挑战。